Companies To Watch

  1. Companies To Watch: Arena Pharmaceuticals 9/8/2017

    By early 2016, Arena’s board decided to remake the company, beginning with new management and a new strategy. Since then, the company has evolved back to a core drug development platform.

  2. Companies To Watch: ProMIS Neurosciences 8/9/2017

    ProMIS Neurosciences believes inaccurate targeting of mAbs is to blame, in fact, for lack of progress against Alzheimer’s disease.

  3. Companies To Watch: GeNeuro 7/7/2017

    Outside skepticism about GeNeuro’s scientific concept has made fund-raising even harder than usual for a startup. But the Swiss company has found considerable support in Europe.

  4. Companies To Watch: Frequency Therapeutics 6/7/2017

    Frequency Therapeutics is an early-stage developer of small molecule drugs to activate “progenitor cells” and restore healthy tissue. Its lead program is in treating hearing loss by regenerating sensory cells in the inner ear, for which it is planning a Phase 1 trial to launch in mid-2018.

  5. Companies To Watch: Noveome Biotherapeutics 5/9/2017

    To heal the wounds — maintaining and restoring cellular homeostasis with novel secretomes.

  6. Companies To Watch: Aridis Pharmaceuticals 4/7/2017

    An anti-infective immunotherapy developer on a mission to replace antibiotics with engineered antibodies and novel mechanisms.

  7. Companies To Watch: Edge Therapeutics 3/8/2017

    In Phase 3 with an innovatively delivered drug to treat a deadly complication of ruptured brain aneurysm.

  8. A Progress Report On The 2016 Companies To Watch 2/1/2017

    There is no grand plan for a whole year of Companies to Watch (CtW). Each month, a single candidate makes the cut for a single column. Nevertheless, patterns emerge among the CtWs as the year progresses and come into focus as it ends.

  9. Companies To Watch: Ritter Pharmaceuticals 1/1/2017

    On a mission to develop the first FDA-approved, durable-efficacy therapeutic for lactose intolerance

  10. Companies To Watch: Catabasis 11/1/2016

    There is an obvious, timely issue with Catabasis that deserves observation but should not eclipse the whole of the company — its Phase 2 candidate for treating DMD.